HOME >> BIOLOGY >> NEWS
Virulence molecules found for poultry bursal virus

COLLEGE PARK, Md.--The molecular keys to the serious poultry disease, known as Gumboro disease, have been discovered for the first time by scientists of the University of Maryland Biotechnology Institute and the Virginia-Maryland Regional College of Veterinary Medicine.

At UMBI's Center for Agricultural Research (CAB), virologist Vikram N. Vakharia and colleagues report finding specific amino acid residues in the Gumboro-causing viruses that are responsible for its infection, virulence and disease development in poultry.

In the late 1980's, concern was heightened in the poultry industry of the Delmarva (Delaware/Maryland/Virginia) Peninsula when researchers found new strains of infectious bursal disease virus (IBDV) that causes serious disease. The region produces over 600 million broiler chickens annually. The IBDV strains found there caused wasting away of the bursa, which is the major immunological organ of chickens, but did not cause the hemorrhaging condition and high death rates of earlier, so-called classic, strains found in the United States in the 1960's. However in the 1990's, strains of IBDV emerged in Europe and Asia that killed up to 70 percent of some chicken flocks.

UMBI's Vakharia has recently created new, cost-effective recombinant vaccines to fight IBDV. However, the unpredictable nature of the Gumboro outbreaks, from mild to severe, is due to the ability of the virus to mutate and adapt in chicken tissues and continue to threaten the industry.

The discovery of the virus amino acids responsible for severe outbreaks will now help Vakaria to more rapidly respond to new strains of the virus with even more effective genetically engineered vaccines that can be administered to the chicken but will not cause the disease, while producing a strong protective immune response.

In the December 2001 issue of the Journal of Virology, the scientists report that three
'"/>

Contact: Steve Berberich
berberic@umbi.umd.edu
301-738-6295
University of Maryland Biotechnology Institute
7-Feb-2002


Page: 1 2

Related biology news :

1. Vions TAPET Organisms Demonstrate Reduced Virulence, Increased Safety While Retaining Ability To Specifically Target Tumors
2. Tiny molecules have big potential as cancer drugs, Stanford researcher believes
3. Synthesized molecules studied as weapon to stop cell division in cancer cells
4. Scientists reinvent DNA as template to produce organic molecules
5. Sweet success in targeting sugar molecules to cells in living animals
6. UC Riverside researcher takes snapshots of the movement of molecules in a billionth of a second
7. Scientists pinpoint molecules that generate synapses
8. Two molecules work together to aid transport of immune cells, UT Southwestern researchers find
9. Controlling biomolecules with magnetic tweezers
10. Water molecules clump more loosely than previously thought
11. Creating polymers that act like biomolecules

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Virulence molecules found for poultry bursal virus

(Date:5/21/2013)... largest gathering of biomass experts , Where? ... When? 03-07 June 2013 , ... research, resource assessment, market and policy developments, manufacturing and ... world and benefiting from its 2013 edition from a ... than 60 countries, more than 240 plenary and oral ...
(Date:5/21/2013)... epigenetic modifications, which alter the way genes function ... be detected in the blood of pregnant women ... to foretell depression in the weeks after giving ... become debilitating. , The findings of the small ... in the journal Molecular Psychiatry . , ...
(Date:5/20/2013)... the effect of physical education (PE) on child weight, ... increasing the amount of time that elementary schoolchildren spent ... The study represents some of the first evidence of ... is forthcoming in the Journal of Health Economics ... can be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 , The ...
Breaking Biology News(10 mins):21st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Gym class reduces probability of obesity, study finds for first time 2
(Date:5/21/2013)... Wisc. (PRWEB) May 21, 2013 ... parts distributor , will be exhibiting for the ... Advancement of Medical Instrumentation (AAMI) 2013 Conference and ... purchase, support, distribute, and manufacture healthcare technologies. This ... in Long Beach, California. , The three-day ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 ... financial services company for clinical trials, announced today ... Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical ... investigator payment process. SpendMD ™, Aggregate ... complete solution for tracking and reporting transfer of ...
(Date:5/21/2013)... Canada (PRWEB) May 21, 2013 ... is a strong push within the industry to ... and Manufacturing Organizations and pharma companies often means ... frames. , Microtablets, developed in collaboration with Sensidose ... effective outsourcing can bring products to market sooner. ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: